

**Senate File 552 - Introduced**

SENATE FILE 552  
BY COMMITTEE ON HEALTH AND HUMAN  
SERVICES

(SUCCESSOR TO SSB 1138)

**A BILL FOR**

1 An Act relating to a review of anti-obesity medications by the  
2 department of health and human services and the department of  
3 administrative services for purposes of the medical assistance  
4 program and health insurance plans for state employees.  
5 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:

unofficial

1 Section 1. ANTI-OBESITY MEDICATION REVIEW AND REPORT. For  
2 purposes of the medical assistance program under chapter 249A  
3 and health insurance plans for state employees established  
4 pursuant to chapter 509A, the department of health and human  
5 services and the department of administrative services shall  
6 review anti-obesity medications, including GLP-1 agonists,  
7 for effectiveness relating to weight loss, the impact  
8 on comorbidities, the potential for cost savings due to  
9 deferred medical procedures and reduced medications related to  
10 comorbidity, recommended eligibility requirements, any short-term  
11 and long-term costs associated with coverage, and any other  
12 criteria the departments deem relevant. The department of  
13 health and human services and the department of administrative  
14 services shall submit a report to the general assembly by January  
15 5, 2026, with the departments' findings, proposed eligibility  
16 requirements, and any short-term and long-term costs associated  
17 with coverage.

18 EXPLANATION

19 The inclusion of this explanation does not constitute agreement with  
20 the explanation's substance by the members of the general assembly.

21 This bill relates to the department of health and human  
22 services (HHS) and the department of administrative services  
23 (DAS) review of anti-obesity medication for purposes of the  
24 medical assistance program and health insurance plans for state  
25 employees established pursuant to Code chapter 509A.

26 The bill requires HHS and DAS to review anti-obesity  
27 medications, including GLP-1 agonists, for effectiveness,  
28 comorbidities, cost savings, eligibility requirements, and  
29 short-term and long-term costs associated with coverage. HHS and  
30 DAS shall submit a report to the general assembly by January 5,  
31 2026, containing HHS's and DAS's findings, proposed eligibility  
32 requirements, and any short-term and long-term costs associated  
33 with coverage.